ACTIVE_NOT_RECRUITING

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions

Chronic Graft vs Host Disease Chronic Graft-Versus-Host Disease Bronchiolitis Obliterans Syndrome Optimal Biologic Dose Safety Chronic Graft-Versus-Host Disease (cGVHD)Inflammatory Lung Disease FEV1

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: Bronchiolitis obliterans syndrome (BOS) is a complication people can experience after hematopoietic stem cell transplant. It usually affects people with chronic graft versus host disease (cGVHD). This occurs when donor stem cells attack the cells of the person who received them. BOS reduces airflow and oxygen levels in the body. It may be caused by neutrophil elastase in the body. Researchers believe the new drug alvelestat (MPH966) may help. Objectives: To test the safety of alvelestat (MPH966) and see what dose best inhibits neutrophil elastase in people with BOS after a stem cell transplant. To study how well the best dose improves lung function in those people. Eligibility: Adults 18 and older who have had a hematopoietic stem cell transplant and have cGVHD and BOS. Design: Participants will be screened with a medical history, physical exam, and blood and urine tests. They will have lung function and heart function tests. They will have computed tomography scans of the chest. Study part 1: Participants will take the starting dose of the study drug by mouth twice a day for 14 days. This is 1 cycle. They will get different doses, for up to 4 cycles. Study part 2: Participants will take the study drug twice a day by mouth at the dose set in part 1, for up to 12 months. Participants will keep medicine diaries. Participants will have several study visits. These may include: Repeats of the screening tests. Bronchoscopy with bronchoalveolar lavage. Sputum samples taken. 6-minute walking test. cGVHD assessment and answer questions. Participants will be contacted after the study for up to 24 months.

Official Title

A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Quick Facts

Study Start:2016-04-28

Study Completion:2027-12-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT02669251

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients must have undergone hematopoietic stem cell transplantation and have moderate to severe chronic GVHD as defined by the NIH consensus criteria. * Patients must have BOS as defined by either of the two following criteria (A or B): * FEV1/vital capacity \<0.7 or the fifth percentile of predicted * FEV1 \<75% of predicted with \>= 10% decline over less than 2 years. FEV1 should not correct to \>75% with albuterol * Absence of infection in the respiratory tract * One of the 2 supporting features of BOS: 1. Evidence of air trapping by expiratory CT or small airway thickening or bronchiectasis by high-resolution CT, or 2. Evidence of air trapping by PFTs: residual volume \>120% predicted or residual volume/total lung capacity elevated outside the 90% confidence interval. * FEV1/vital capacity \>0.7 * FEV1 \<75% of predicted with \>= 10% decline over less than 2 years. FEV1 should not correct to \>75% with albuterol * Absence of infection in the respiratory tract * One of the supporting features of BOS: 1. Evidence of air trapping by expiratory CT 2. small airway thickening or bronchiectasis by high-resolution CT 3. Evidence of air trapping by PFTs: residual volume \>120% predicted or residual volume/total lung capacity elevated outside the 90% confidence interval. * For the Phase 1b study, patients may have had the diagnosis of BOS for any period of time. For the Phase 2 study, patients must be within 5 years from the time of diagnosis. Patients may be at any time interval after SCT as long as the criteria for chronic GVHD and BOS are met. * If patients are taking systemic therapy for cGVHD at the time of enrollment, they must be receiving stable or tapering doses within the previous 4 weeks. Patients are not required to have completed a course of steroids prior to enrollment. * Age \>=18 years. * Karnofsky \>=60% * Patients must have adequate organ and marrow function as defined below: * Leukocytes \>=3,000/mcL * Absolute neutrophil count \>=1,000/mcL * Platelets \>=50,000/mcL * Total bilirubin \<=3 x institutional upper limit of normal, unless there is a known history of Gilbert's disease * AST(SGOT)/ALT(SGPT) \<=2 x institutional upper limit of normal * Serum creatinine \<=1.5 mg/dL OR Creatinine clearance \>=60 mL/min as estimated by GFR per DLM standards * Patients will be required to have received prior treatment with a regimen consisting of inhaled steroids and montelukast +/- azithromycin for at least 3 months prior to enrollment, unless there is evidence of progression or unsatisfactory response while on this regimen prior to 3 months of treatment, as deemed by the treating or referring physician. Patients who are on azithromycin will need to discontinue for at least 2 weeks prior to enrollment. * Agree to adhere to methods of contraception and other fertility control measures:	* FEV1 \<30% (based on absolute percent predicted using USA-ITS-NIH equation) on pulmonary function testing * Patients with clinically relevant abnormal ECG findings, including abnormal QTc\>500 ms on screening ECG (Note: If a patient has a QTc interval \>500 ms on screening ECG, the screening ECG may be repeated twice \[at least 24 hours apart\] for a total of 3 ECGs). * Patients who are receiving any other investigational agents * Recurrent or progressive malignancy requiring anticancer treatment * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, acute kidney injury, or psychiatric illness/social situations within the previous 4 weeks that would limit compliance with study requirements. * Pregnant women are excluded from this study because the teratogenic effects of alvelestat (MPH966) are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with alvelestat (MPH966), nursing should be discontinued if the mother is treated with this agent. * Prior use of neutrophil elastase inhibitors * Patients with a history of cirrhosis, esophageal varices, ascites and hepatic encephalopathy * History of other chronic diseases (i.e., metabolic associated steatohepatitis (MASH), autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis) * Patients with a history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening. NOTE: Patients must also be willing to refrain from drinking alcohol during study participation, until end of study drug administration

Inclusion Criteria

Exclusion Criteria

* Patients must have undergone hematopoietic stem cell transplantation and have moderate to severe chronic GVHD as defined by the NIH consensus criteria.
* Patients must have BOS as defined by either of the two following criteria (A or B):
* FEV1/vital capacity \<0.7 or the fifth percentile of predicted
* FEV1 \<75% of predicted with \>= 10% decline over less than 2 years. FEV1 should not correct to \>75% with albuterol
* Absence of infection in the respiratory tract
* One of the 2 supporting features of BOS:
1. Evidence of air trapping by expiratory CT or small airway thickening or bronchiectasis by high-resolution CT, or
2. Evidence of air trapping by PFTs: residual volume \>120% predicted or residual volume/total lung capacity elevated outside the 90% confidence interval.
* FEV1/vital capacity \>0.7
* FEV1 \<75% of predicted with \>= 10% decline over less than 2 years. FEV1 should not correct to \>75% with albuterol
* Absence of infection in the respiratory tract
* One of the supporting features of BOS:
1. Evidence of air trapping by expiratory CT
2. small airway thickening or bronchiectasis by high-resolution CT
3. Evidence of air trapping by PFTs: residual volume \>120% predicted or residual volume/total lung capacity elevated outside the 90% confidence interval.
* For the Phase 1b study, patients may have had the diagnosis of BOS for any period of time. For the Phase 2 study, patients must be within 5 years from the time of diagnosis. Patients may be at any time interval after SCT as long as the criteria for chronic GVHD and BOS are met.
* If patients are taking systemic therapy for cGVHD at the time of enrollment, they must be receiving stable or tapering doses within the previous 4 weeks. Patients are not required to have completed a course of steroids prior to enrollment.
* Age \>=18 years.
* Karnofsky \>=60%
* Patients must have adequate organ and marrow function as defined below:
* Leukocytes \>=3,000/mcL
* Absolute neutrophil count \>=1,000/mcL
* Platelets \>=50,000/mcL
* Total bilirubin \<=3 x institutional upper limit of normal, unless there is a known history of Gilbert's disease
* AST(SGOT)/ALT(SGPT) \<=2 x institutional upper limit of normal
* Serum creatinine \<=1.5 mg/dL OR Creatinine clearance \>=60 mL/min as estimated by GFR per DLM standards
* Patients will be required to have received prior treatment with a regimen consisting of inhaled steroids and montelukast +/- azithromycin for at least 3 months prior to enrollment, unless there is evidence of progression or unsatisfactory response while on this regimen prior to 3 months of treatment, as deemed by the treating or referring physician. Patients who are on azithromycin will need to discontinue for at least 2 weeks prior to enrollment.
* Agree to adhere to methods of contraception and other fertility control measures:

* FEV1 \<30% (based on absolute percent predicted using USA-ITS-NIH equation) on pulmonary function testing
* Patients with clinically relevant abnormal ECG findings, including abnormal QTc\>500 ms on screening ECG (Note: If a patient has a QTc interval \>500 ms on screening ECG, the screening ECG may be repeated twice \[at least 24 hours apart\] for a total of 3 ECGs).
* Patients who are receiving any other investigational agents
* Recurrent or progressive malignancy requiring anticancer treatment
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, acute kidney injury, or psychiatric illness/social situations within the previous 4 weeks that would limit compliance with study requirements.
* Pregnant women are excluded from this study because the teratogenic effects of alvelestat (MPH966) are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with alvelestat (MPH966), nursing should be discontinued if the mother is treated with this agent.
* Prior use of neutrophil elastase inhibitors
* Patients with a history of cirrhosis, esophageal varices, ascites and hepatic encephalopathy
* History of other chronic diseases (i.e., metabolic associated steatohepatitis (MASH), autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis)
* Patients with a history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening. NOTE: Patients must also be willing to refrain from drinking alcohol during study participation, until end of study drug administration

Contacts and Locations

Principal Investigator

Najla El Jurdi, M.D.

PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

Najla El Jurdi, M.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-04-28

Study Completion Date2027-12-01

Study Record Updates

Study Start Date2016-04-28

Study Completion Date2027-12-01

Terms related to this study

Keywords Provided by Researchers

Optimal Biologic Dose
Safety
Chronic Graft-Versus-Host Disease (cGVHD)
Inflammatory Lung Disease
FEV1

Additional Relevant MeSH Terms

Chronic Graft vs Host Disease
Chronic Graft-Versus-Host Disease
Bronchiolitis Obliterans Syndrome